✦ LIBER ✦

Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib

✍ Scribed by M. Birch; P. E. Morgan; S. Handley; A. Ho; R. Ireland; R. J. Flanagan

Book ID: 115551105
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 734 KB
Volume: aop
Category: Article
ISSN: 0269-3879
DOI: 10.1002/bmc.2796

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Drug interactions with the tyrosine kina

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

✍ Haouala, A.; Widmer, N.; Duchosal, M. A.; Montemurro, M.; Buclin, T.; Decosterd, 📂 Article 📅 2011 🏛 American Society of Hematology 🌐 English ⚖ 103 KB

Liquid chromatography–tandem mass spectr

Liquid chromatography–tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma

✍ Rolf W. Sparidans; Tahani T.A. Ahmed; Eline W. Muilwijk; Marieke E.B. Welzen; Ja 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 287 KB

A potential role for imatinib and other

A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis

✍ Yuval Bibi; Alice B. Gottlieb 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 235 KB

Determination of drug synergism between

Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines

✍ IoannisA. Avramis; WalterE. Laug; EdwardA. Sausville; VassiliosI. Avramis 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 347 KB

Simple and accurate high-performance liq

Simple and accurate high-performance liquid chromatographic method for the measurement of three antiepileptics in therapeutic drug monitoring

✍ Yukimitsu Kouno; Chiyoji Ishikura; Masoto Homma; Kitaro Oka 📂 Article 📅 1993 🏛 Elsevier Science ⚖ 466 KB

Phase I pharmacokinetic study of the vas

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

✍ David A. Reardon; Merrill J. Egorin; Annick Desjardins; James J. Vredenburgh; Ja 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 1 views